A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, vol.408, pp.979-982, 2000. ,
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, vol.408, pp.982-985, 2000. ,
Immunization with amyloid-beta attenuates Alzheimerdisease-like pathology in the PDAPP mouse, Nature, vol.400, pp.173-177, 1999. ,
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology, vol.64, pp.1553-1562, 2005. ,
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization, Neurology, vol.61, pp.46-54, 2003. ,
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled Phase I trial, Lancet, vol.372, pp.216-223, 2008. ,
Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study, Lancet Neurol, vol.11, pp.597-604, 2012. ,
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, Alzheimers Dement, vol.8, pp.261-271, 2012. ,
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab, Arch Neurol, vol.69, pp.198-207, 2012. ,
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease, Neurology, vol.73, pp.2061-2070, 2009. ,
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study, Lancet Neurol, vol.9, pp.363-372, 2010. ,
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease, Arch Neurol, vol.69, pp.1002-1010, 2012. ,
Natural human antibodies to amyloid beta peptide, Autoimmun Rev, vol.7, pp.415-420, 2008. ,
Intravenous immunoglobulin for treatment of mild-tomoderate Alzheimer's disease: A Phase 2, randomised, double-blind, placebo-controlled, dose-finding trial, Lancet Neurol, vol.12, pp.233-243, 2013. ,
Intracellular amyloid-beta in Alzheimer's disease, Nat Rev Neurosci, vol.8, pp.499-509, 2007. ,
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo, Nat Med, vol.11, pp.556-561, 2005. ,
A specific amyloid-beta protein assembly in the brain impairs memory, Nature, vol.440, pp.352-357, 2006. ,
Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice, EMBO J, vol.27, pp.224-233, 2008. ,
Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease, Nat Neurosci, vol.15, pp.1422-1429, 2012. ,
Similar amyloid-{beta} burden in posterior cortical atrophy and Alzheimer's disease, Brain, vol.134, pp.2036-2043, 2011. ,
Twoyear follow-up of amyloid deposition in patients with Alzheimer's disease, Brain, vol.129, pp.2805-2807, 2006. ,
Alzheimer's drugs take a new tack, Nature, vol.489, pp.13-14, 2012. ,
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model, Nat Neurosci, vol.5, pp.452-457, 2002. ,
Reversible memory loss in a mouse transgenic model of Alzheimer's disease, J Neurosci, vol.22, pp.6331-6335, 2002. ,
Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice, J Biol Chem, vol.281, pp.4292-4299, 2006. ,
Preclinical Alzheimer disease-the challenges ahead, Nat Rev Neurol, vol.9, pp.54-58, 2012. ,
MHC-independent genetic factors control the magnitude of CD4 T cell responses to amyloid-beta peptide in mice through regulatory T cell-mediated inhibition, J Immunol, vol.187, pp.4492-4500, 2011. ,
Distinct patterns of antiamyloid-beta antibodies in typical and atypical Alzheimer disease, Arch Neurol, vol.69, pp.1181-1185, 2012. ,
CD 4 T cells in the pathobiology of neurodegenerative disorders, J Neuroimmunol, vol.211, pp.3-15, 2009. ,
Inflammation in Alzheimer disease: Driving force, bystander or beneficial response, Nat Med, vol.12, pp.1005-1015, 2006. ,
Reversal of paralysis and reduced inflammation from peripheral administration of beta-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis, Sci Transl Med, vol.4, pp.145-105, 2012. ,
Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline, Nat Med, vol.18, pp.1812-1819, 2012. ,
Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy, Acta Neuropathol, vol.118, pp.87-102, 2009. ,
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice, CNS Neurol Disord Drug Targets, vol.8, pp.50-64, 2009. ,
, Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain, vol.131, pp.3299-3310, 2008.
CD4() T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid betarelated angiitis, Arch Neurol, vol.69, pp.773-777, 2012. ,
VBM anticipates the rate of progression of Alzheimer disease: A 3-year longitudinal study, Neurology, vol.70, pp.2201-2211, 2008. ,
Age and rate of cognitive decline in Alzheimer disease: Implications for clinical trials, Arch Neurol, vol.69, pp.901-905, 2012. ,
Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers, Brain, vol.134, pp.293-300, 2011. ,
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.280-292, 2011. ,
Amyloid-beta-associated clinical decline occurs only in the presence of elevated P-tau, Arch Neurol, vol.69, pp.709-713, 2012. ,
Asymptomatic Alzheimer's disease: A prodrome or a state of resilience?, Curr Alzheimer Res, vol.8, pp.330-335, 2011. ,
T cell deficiency leads to cognitive dysfunction: Implications for therapeutic vaccination for schizophrenia and other psychiatric conditions, Proc Natl Acad Sci U S A, vol.101, pp.8180-8185, 2004. ,
Systemic inflammatory cells fight off neurodegenerative disease, Nat Rev Neurol, vol.6, pp.405-410, 2010. ,
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model, J Neurosci, vol.30, pp.16559-16566, 2010. ,
Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of Tau pathology and delay of disease progression, J Biol Chem, vol.286, pp.34457-34467, 2011. ,
Targeting phospho-Ser422 by active tau immunotherapy in the THYTau22 mouse model: A suitable therapeutic approach, Curr Alzheimer Res, vol.9, pp.397-405, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00664452
How to get from here to there: Macrophage recruitment in Alzheimer's disease, Current Alzheimer Res, vol.8, pp.156-163, 2011. ,